--- title: "Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Update" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/280904911.md" description: "Sino Biopharmaceutical (OTCMKTS:SBMFF) experienced a significant increase in short interest in March, rising 35.7% to 98,069,575 shares as of March 13th. This represents 0.5% of the company's shares sold short, with a days-to-cover ratio of 212,271.8 days based on an average trading volume of 462 shares. The stock opened at $0.76, with a 52-week range of $0.45 to $1.24. Analysts currently rate the stock as a Hold, but suggest other stocks may be better investment options." datetime: "2026-03-29T09:58:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280904911.md) - [en](https://longbridge.com/en/news/280904911.md) - [zh-HK](https://longbridge.com/zh-HK/news/280904911.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280904911.md) | [English](https://longbridge.com/en/news/280904911.md) # Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Update Sino Biopharmaceutical (OTCMKTS:SBMFF - Get Free Report) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 98,069,575 shares, an increase of 35.7% from the February 26th total of 72,283,620 shares. Approximately 0.5% of the company's stock are sold short. Based on an average trading volume of 462 shares, the days-to-cover ratio is currently 212,271.8 days. Get **Sino Biopharmaceutical** alerts: ## Sino Biopharmaceutical Stock Performance SBMFF opened at $0.76 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.28 and a current ratio of 1.36. The firm's 50-day moving average price is $0.84 and its 200-day moving average price is $0.90. Sino Biopharmaceutical has a 52-week low of $0.45 and a 52-week high of $1.24. ## About Sino Biopharmaceutical (Get Free Report) Sino Biopharmaceutical Limited OTCMKTS: SBMFF is a Hong Kong–incorporated investment holding company principally engaged in the pharmaceutical sector. Founded in 2000 and listed on the Hong Kong Stock Exchange in 2006, the company has developed an integrated business model that spans research and development, manufacturing and commercialization of healthcare products. Through its subsidiaries, Sino Biopharmaceutical focuses on enhancing China's domestic pharmaceutical infrastructure while expanding its footprint across key therapeutic areas. The company's product portfolio is organized into three core segments: infusion solutions, small-molecule synthetic pharmaceuticals and innovative biologics. ## Featured Stories - Five stocks we like better than Sino Biopharmaceutical _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Sino Biopharmaceutical Right Now? Before you consider Sino Biopharmaceutical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sino Biopharmaceutical wasn't on the list. While Sino Biopharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### 相關股票 - [SIHUAN PHARM PREF OFFER (44080.HK)](https://longbridge.com/zh-HK/quote/44080.HK.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [SBP GROUP (01177.HK)](https://longbridge.com/zh-HK/quote/01177.HK.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [SPDR S&P Health (XHS.US)](https://longbridge.com/zh-HK/quote/XHS.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) - [Navidea Biopharm (NAVB.US)](https://longbridge.com/zh-HK/quote/NAVB.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md) ## 相關資訊與研究 - [Lupin gets tentative nod from USFDA for generic Sugammadex injection](https://longbridge.com/zh-HK/news/281130232.md) - [Telehealth firm WeightWatchers' CEO departs company](https://longbridge.com/zh-HK/news/281657028.md) - [Idorsia Ltd (IDIA) Receives a Rating Update from a Top Analyst](https://longbridge.com/zh-HK/news/281283879.md) - [Merck's Enlicitide Decanoate Shows Greater LDL-C Reduction Than Oral Non-Statins At 8 Weeks](https://longbridge.com/zh-HK/news/281051985.md) - [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/zh-HK/news/281015927.md)